SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
18640031
Source:
http://linkedlifedata.com/resource/pubmed/id/18640031
Search
Subject
(
63
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0027651
,
umls-concept:C0030705
,
umls-concept:C0144576
,
umls-concept:C0205179
,
umls-concept:C0205208
,
umls-concept:C0332174
,
umls-concept:C0920321
,
umls-concept:C1176309
pubmed:issue
13
pubmed:dateCreated
2008-8-25
pubmed:abstractText
The combination of a proteasome inhibitor with a taxane has potential clinical synergism that prompted a clinical test.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/9005373
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids
,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel
,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines
,
http://linkedlifedata.com/resource/pubmed/chemical/bortezomib
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1879-0852
pubmed:author
pubmed-author:BertoniFF
,
pubmed-author:CapriGG
,
pubmed-author:CatapanoC VCV
,
pubmed-author:CrestaSS
,
pubmed-author:GalleraniEE
,
pubmed-author:GianniLL
,
pubmed-author:MaccioniEE
,
pubmed-author:MaurMM
,
pubmed-author:PassalacquaDD
,
pubmed-author:RinaldiAA
,
pubmed-author:SessaCC
,
pubmed-author:TostII
,
pubmed-author:ViganòLL
pubmed:issnType
Electronic
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1829-34
pubmed:meshHeading
pubmed-meshheading:18640031-Adult
,
pubmed-meshheading:18640031-Aged
,
pubmed-meshheading:18640031-Antineoplastic Combined Chemotherapy Protocols
,
pubmed-meshheading:18640031-Boronic Acids
,
pubmed-meshheading:18640031-Breast Neoplasms
,
pubmed-meshheading:18640031-Female
,
pubmed-meshheading:18640031-Humans
,
pubmed-meshheading:18640031-Infusions, Intravenous
,
pubmed-meshheading:18640031-Male
,
pubmed-meshheading:18640031-Maximum Tolerated Dose
,
pubmed-meshheading:18640031-Middle Aged
,
pubmed-meshheading:18640031-Ovarian Neoplasms
,
pubmed-meshheading:18640031-Paclitaxel
,
pubmed-meshheading:18640031-Prostatic Neoplasms
,
pubmed-meshheading:18640031-Pyrazines
,
pubmed-meshheading:18640031-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
pubmed:affiliation
Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy.
pubmed:publicationType
Journal Article
,
Research Support, Non-U.S. Gov't
,
Multicenter Study
,
Clinical Trial, Phase I